IngredientsThe organism commonly marketed and discussed under the name Bifidobacterium lactis is now formally classified as Bifidobacterium animalis subsp. lactis, as the species designation B. lactis was later shown not to fulfill the criteria for a full species and was instead included in Bifidobacterium animalis as a subspecies. The name B. lactis persists widely in the scientific and commercial literature as a convenient abbreviation. Legacy commercial names include "Bifidus lactis" and the abbreviation "B. animalis ssp. lactis."
The species was previously described by Meile et al. and characterized by its high oxygen resistance and production of considerable amounts of formate. The phylogenetic position of B. lactis DSM 10140, defined by sequence similarity and sequence analysis of the ldh gene, revealed that B. animalis ATCC 25527 is the most closely related strain. Cai et al. published DNA–DNA hybridisation results showing that Bifidobacterium lactis did not differ enough from Bifidobacterium animalis to allow species status, and on the basis of those results, the International Committee on Systematic Bacteriology, Subcommittee on the taxonomy of Bifidobacterium, Lactobacillus and related organisms decided that Bifidobacterium lactis cannot be acknowledged as a valid species. A subsequent polyphasic taxonomic analysis led to the creation of two subspecies within Bifidobacterium animalis, and the commercially important strain Bb-12® belongs to the subspecies B. animalis subsp. lactis.
The scientific classification places this organism in: Domain: Bacteria; Phylum: Actinomycetota (Actinobacteria); Class: Actinomycetia; Order: Bifidobacteriales; Family: Bifidobacteriaceae; Genus: Bifidobacterium; Species: B. animalis; Subspecies: lactis.
The type strain of Bifidobacterium lactis is deposited under the collection accession numbers CCUG 37979, CIP 105265, DSM 10140, JCM 10602, and BCCM/LMG 18314.
Bifidobacterium is a genus of lactic-acid-producing, Gram-positive, non-spore-forming, non-motile, anaerobic bacteria. BB-12® is a catalase-negative, rod-shaped bacterium. As a living microbial organism, it has a genome of approximately 1.9–2.2 Mb rather than a single chemical formula. The complete genome sequence of BB-12® has been determined and published.
Common commercially characterized strains include BB-12®, HN019, CNCM I-3446 (BI-07), BL-04, and B420, with strain designations varying by manufacturer. BB-12® is described in more than 300 scientific publications, of which more than 130 are publications of human clinical studies, making it the world's most documented probiotic Bifidobacterium. Based on DNA fingerprints, the well-known strain DR10™ should also be correctly designated as B. animalis subsp. lactis; in the literature this strain is also referred to as Bifidobacterium lactis HN019 and HOWARU™ Bifido.
Historically, B. animalis subsp. lactis has been isolated from human and animal intestinal microbiota as well as from dairy fermentations. Bifidobacteria are one of the early colonizers of the newborn gut, and their absence has been associated with a range of negative health outcomes in infants. Levels of bifidobacteria are reduced in adults, and the distribution of species differs significantly compared to infants.
Commercial manufacture uses pure-culture fermentation, cell harvest, cryoprotectants, lyophilization or spray drying, and quality control procedures including strain identification, purity testing, and CFU stability verification. BB-12® has been used in infant formula, dietary supplements, and fermented milk products worldwide. Clinical trials have delivered the organism in fermented dairy products (yogurts, yogurt smoothies), freeze-dried capsules, and chewable tablets. Studies examining delivery matrices have compared B. animalis subsp. lactis BB-12 at approximately 1010 CFU/day delivered via yogurt smoothie versus capsule in a randomized, four-period, crossover study of 36 adults. BB-12® has demonstrated high stability in foods and as freeze-dried powders.
Bifidobacteria were first discovered and isolated from the feces of a breast-fed infant in 1899 and are common constituents of the indigenous microbiota in the human intestinal tract. In 1899, Henri Tissier, a French pediatrician at the Pasteur Institute in Paris, isolated a bacterium characterized by a Y-shaped morphology ("bifid") in the intestinal microbiota of breast-fed infants and named it "bifidus."
B. animalis subsp. lactis rose to commercial prominence from the 1990s onward with strain banking and clinical trials. The BB-12® strain was deposited in the cell culture bank of Chr. Hansen in 1983. At the time of isolation, BB-12® was considered to belong to the species Bifidobacterium bifidum, and modern molecular classification techniques subsequently reclassified it first as Bifidobacterium animalis and later to the new species Bifidobacterium lactis.
Strains from the Bifidobacterium genus have long been utilized as probiotic microbes; they are key gut commensals across all life stages and have a history of safe use, demonstrated survivability in the gastrointestinal tract, and evidence of health-promoting benefits. Historically, bifidobacteria were consumed via yogurt and cultured milk products to promote digestive comfort and preservation. No single traditional medical culture holds a documented, named prescriptive use for B. animalis subsp. lactis as a distinct entity prior to the era of industrial microbiology, because the organism was not taxonomically delineated until 1997; its history is therefore embedded within the broader tradition of fermented dairy consumption and the empirical observation that cultured milk products supported digestive wellbeing.
Bifidobacterial species have been found to be involved in the biosynthesis of a wide range of health-promoting active compounds, including short-chain fatty acids (SCFAs), vitamins, and organic acids. The primary fermentation end-products relevant to host physiology include acetate and lactate, which are produced from carbohydrate fermentation by the bifid shunt (the fructose-6-phosphate phosphoketolase pathway), a metabolic route unique to bifidobacteria.
BB-12® exhibits excellent gastric acid and bile tolerance; it contains bile salt hydrolase, and has strong mucus adherence properties, all valuable probiotic characteristics. Bile salt hydrolase (BSH) activity enables the deconjugation of primary bile salts in the intestinal lumen, a process with implications for cholesterol metabolism and colonization persistence.
Short-chain fatty acids (SCFAs), which are metabolites derived from the fermentation of dietary fibre by the gut microbiota, are important for host metabolic health. Studies have evaluated whether B. animalis subsp. lactis GCL2505, a probiotic strain capable of proliferating and increasing SCFA levels in the gut, exerts anti-metabolic-syndrome effects via the SCFA receptor G protein-coupled receptor 43 (GPR43). Analyses of GPR43-knockout mice clearly demonstrated that GCL2505 can promote the production of SCFA in the gut, which function as an essential factor mediating host metabolic homeostasis in a GPR43-dependent manner.
Cell-surface proteins, exopolysaccharides, and lipoteichoic acids characteristic of Gram-positive bacteria play roles in mucus and epithelial adhesion and in immune cell recognition. Characterization and purification studies indicate that BB-12's anti-inflammatory factors might include a 50-kDa proteinaceous compound that is stable under a variety of heat and pH conditions.
BB-12® exhibits excellent gastric acid and bile tolerance, contains bile salt hydrolase, and has strong mucus adherence properties, all valuable probiotic characteristics. Clinical studies have demonstrated survival of BB-12® through the gastrointestinal tract, and BB-12® has been shown to support a healthy gastrointestinal microbiota.
Fermentation products from BB-12® increased tight junction strength significantly above that of the untreated control, and in all cases fermentation products from BB-12® induced the greatest increase in transepithelial resistance (TER) compared to other strains tested; these in vitro changes indicate that BB-12® may increase tight junction strength and protect against disruption of the epithelial barrier function.
Research supports the hypothesis that B. lactis HN019â„¢ has a beneficial role in maintaining intestinal barrier function during gastrointestinal infections by competing and excluding potential pathogens via different mechanisms, maintaining normal tight junction function in vitro, and regulating host immune defense toward pathogens in both in vitro and human studies.
Immune interaction is increasingly being acknowledged as a substantial probiotic mechanism; probiotics are capable of communicating with and affecting the immune system through immune cells located in the intestine, and seventy to eighty percent of the immune cells are associated with the gut mucosa.
Kim and colleagues demonstrated that B. animalis subsp. lactis inhibits NF-κB and NF-κB-regulated genes in intestinal epithelial cells and prevents acute colitis in mice. The inhibitory effect of BB-12 on TNF-α-induced IL-8 expression is mediated through suppression of NF-κB activation in Caco-2 cells.
Pathogen inhibition, barrier function enhancement, and immune interactions are mechanisms that have all been demonstrated for BB-12®. Competitive exclusion — occupying mucosal binding sites and producing organic acids that reduce local pH — is a well-recognized mechanism by which bifidobacteria limit colonization by enteropathogens.
HN019™ reduced intestinal transit time and increased bowel movement frequency in functional constipation, potentially by modulating the gut–brain–microbiota axis, mainly via the serotonin signaling pathway, through short-chain fatty acids derived from microbial fermentation.
SCFAs are essential for gastrointestinal health and are absorbed by colonic epithelial cells, and stimulate Na+-dependent fluid absorption, thereby conserving energy, Na+, and fluid.
BB-12 interacts with the host epithelial lining and cells of the immune system and has a relationship with the gut microbiota. Collectively, the well-documented clinical efficacies demonstrated by BB-12 are most likely not through one single mechanism but through the collective direct and indirect effects the strain has on both its environment and the host.
Summary of evidence: Multiple controlled trials and one dose-ranging trial support effects on transit time and bowel movement frequency, though results are mixed.
A double-blind, randomized, placebo-controlled, dose-ranging trial enrolled 228 adults diagnosed with functional constipation per Rome III criteria and evaluated colonic transit time (CTT) as the primary outcome along with secondary outcomes including PAC-SYM, PAC-QoL, bowel function index, bowel movement frequency, stool consistency, straining, bloating, and pain severity. There were no statistically significant differences in the primary or secondary outcomes between interventions. This was a well-powered trial, but its null primary endpoint for CTT illustrates that results are not uniformly positive.
In contrast, HN019â„¢ reduced intestinal transit time and increased bowel movement frequency in functional constipation in other studies. A 2011 dose-response study (Waller et al., Scandinavian Journal of Gastroenterology) investigated effects of HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. In a large randomized trial in India, B. lactis HN019â„¢ showed efficacy in reducing the incidence of diarrhea and fever during the rainy season; fecal immunoglobulin A and serum IL-8 were also significantly decreased in the HN019â„¢ arm compared to placebo.
BB-12® has been shown to improve bowel function and to have a protective effect against diarrhea.
Strength of evidence: Moderate. Positive trends across several controlled trials for stool frequency and transit outcomes, but at least one rigorously designed dose-ranging RCT found no significant differences in primary endpoints. Strain specificity is important and results cannot be generalized across all B. animalis subsp. lactis preparations.
Summary of evidence: Clinical data, including studies conducted under FDA investigational new drug oversight, support a protective role during and after antibiotic courses.
The administration of broad-spectrum antibiotics is often associated with antibiotic-associated diarrhea (AAD) and impacts gastrointestinal tract homeostasis; evidence in humans that probiotics may enhance the recovery of microbiota populations after antibiotic treatment is equivocal, and few studies have addressed whether probiotics improve recovery of microbial metabolic function.
A randomized, allocation-concealed, controlled trial aimed to determine whether BB-12-containing yogurt could protect against antibiotic-induced fecal SCFA and microbiota composition disruptions; the trial involved amoxicillin/clavulanate administration on days 1–7 in conjunction with either BB-12-containing or control yogurt on days 1–14.
A phase I safety study evaluated the safety of Bifidobacterium animalis subsp. lactis strain BB-12-supplemented yogurt when consumed by generally healthy adults prescribed a 10-day course of antibiotics for respiratory infection, with secondary aims of assessing BB-12's ability to affect expression of whole-blood immune markers associated with cell activation and inflammatory response; the study was a phase I, double-blinded, randomized controlled study conducted in compliance with FDA guidelines for an Investigational New Drug. There was no difference in adverse events between the two groups, and there were no withdrawals from the study for adverse events related to product consumption.
BB-12® has been shown to reduce side effects of antibiotic treatment, such as antibiotic-associated diarrhea.
Strength of evidence: Moderate. Several controlled trials support a protective association, but evidence in humans regarding full microbiota recovery after antibiotics remains equivocal per the authors of reviewed studies themselves.
Summary of evidence: A systematic review and meta-analysis provides the strongest level of evidence for immune endpoints in older populations.
A systematic review of Medline and Embase for controlled trials reporting polymorphonuclear (PMN) cell phagocytic capacity or natural killer (NK) cell tumoricidal activity following B. lactis HN019 consumption in the elderly performed a random-effects meta-analysis; four clinical trials were included. B. lactis HN019 supplementation was highly efficacious in increasing PMN phagocytic capacity with a standardized mean difference (SMD) of 0.74 (95% CI: 0.38–1.11, p < 0.001) and moderately efficacious in increasing NK cell tumoricidal activity with an SMD of 0.43 (95% CI: 0.08–0.78, p = 0.02). The main limitations of this research were the small number of included studies, short-term follow-up, and assessment of a single probiotic strain; in conclusion, daily consumption of B. lactis HN019 enhances NK cell and PMN function in healthy elderly adults.
Clinical studies have shown that BB-12® increases the body's resistance to common respiratory infections and reduces the incidence of acute respiratory tract infections.
Strength of evidence: Moderate-to-good for cellular immune markers in the elderly (meta-analysis of four RCTs, statistically significant). Long-term clinical outcomes such as reduced infection rates require further investigation.
In a double-blinded, placebo-controlled study, 109 newborn 1-month-old infants were randomized to receive either a B. lactis BB-12 tablet or control placebo tablet twice daily until the age of 8 months; the study demonstrated that BB-12 supplementation significantly reduced the incidence of respiratory infections during the first 8 months of life in healthy breastfed infants.
B. lactis HN019â„¢ also supports normal physiological function in immunosenescent elderly and competes and excludes potential pathogens.
Strength of evidence: Preliminary to moderate. Individual controlled trials show effects on respiratory infection incidence in infants; larger confirmatory studies are needed.
Evidence suggests that Bifidobacteria supplementation, which serves to restore a balanced microbial composition, modulates immune function, gut microbiota, and intestinal mucosal adhesion in IBS patients, with studies demonstrating positive effects on epithelial cell adherence, reinforcement of tight junctions, stimulation of IgA production and cell-mediated immunity, which are impaired in IBS patients.
Agrawal and colleagues investigated Bifidobacterium lactis in a fermented milk product consumed daily over a 4-week intervention compared to a daily probiotic-naive placebo non-fermented product; individuals under the treatment condition were found to have significantly lower levels of abdominal pain compared to the control group.
Strength of evidence: Preliminary. Individual trials have shown positive results for abdominal symptoms and transit in IBS with constipation, but the evidence base is not yet sufficiently robust for definitive conclusions, and results vary by strain, IBS subtype, and study design.
The potential of probiotics to control allergic inflammation at an early age was assessed in a randomized, double-blind, placebo-controlled study in which 27 infants (mean age 4.6 months) who manifested atopic eczema during exclusive breastfeeding were weaned to probiotic-supplemented, Bifidobacterium lactis Bb-12 or Lactobacillus strain GG, extensively hydrolysed whey formulas, or to the same formula without probiotics.
Prenatal and postnatal supplementation with a mixture of B. bifidum BGN4, B. lactis AD011, and L. acidophilus AD031 was reported as an effective approach in preventing the development of eczema in infants at high risk of allergy during the first year of life. This was a multi-strain intervention, making it impossible to isolate the contribution of B. lactis alone.
Two studies in a systematic review and meta-analysis on pediatric atopic dermatitis used Bifidobacterium as an intervention, including Bifidobacterium lactis Bb-12 and a Bifidobacterium mixture.
Strength of evidence: Preliminary and mixed. Several trials, many using multi-strain formulations rather than B. lactis alone, have reported reductions in eczema incidence or severity. Isolating the contribution of B. animalis subsp. lactis specifically is difficult given the mixed-strain designs of most studies.
Consumption of BB-12 delivered in a yogurt smoothie or capsule did not significantly alter the composition of the gut microbiota, gut transit times, or fecal SCFA concentration of the study cohort; however, daily consumption of BB-12 in yogurt smoothie may result in higher relative abundance of B. animalis in healthy adults. This finding suggests that the delivery matrix matters for engraftment.
A study aimed to confirm the effects of BB-12 on high-fat diet-induced gut microbiota disorders using human microbiota-associated rats and next-generation sequencing of fecal samples. BB-12 conferred protection on the gut microbiota composition of the rats by increasing the abundance of Prevotella and decreasing the abundance of Clostridium, Blautia, and Bacteroides in the first three weeks, and a Prevotella-dominant enterotype was maintained. This is animal data only and cannot be directly extrapolated to humans.
A randomized, partially blinded, 4-period crossover study examined the effects of B. animalis subsp. lactis BB-12® at 3.16 × 109 CFUs/day on lipids, lipoproteins, and fecal SCFAs in 30 adults aged 18–40 years, measuring serum lipids/lipoproteins, glucose, insulin, C-reactive protein, and fecal SCFAs at baseline and after each treatment period; total cholesterol, LDL-C, HDL-C, and triglycerides did not differ after the probiotic periods versus control.
Fecal SCFAs were negatively associated with total cholesterol, LDL cholesterol, age, and waist circumference. This is an association finding rather than a demonstration of causation.
Strength of evidence: Weak to preliminary for metabolic and lipid endpoints in humans. The randomized crossover trial described above found no significant lipid differences with BB-12® supplementation.
Bifidobacterium lactis is a probiotic subspecies commonly dosed between 1 × 109 and 1 × 1011 CFU/day in clinical trials. Dosages reported in specific studies include:
Delivery forms identified across studies include yogurt, yogurt smoothies, capsules, and tablets. BB-12® originates from Chr. Hansen's collection of dairy cultures and has high stability in foods and as freeze-dried powders.
Bifidobacterium lactis has been present in human food for decades and is listed in the Inventory of Microorganisms With Documented History of Use in Human Food. The European Food Safety Authority has added the species to the Qualified Presumption of Safety list, and the strain BI-04 has self-affirmed GRAS (Generally Recognized As Safe) status from the FDA.
Harmful or toxigenic activities have not been associated with B. lactis, and acquired antibiotic resistance was not detected in B. lactis BI-04 during screening by the EU-funded PROSAFE project. In human clinical studies, BI-04 has been safely used as a single entity and in combination with other probiotics and/or prebiotics, with the ages of subjects in these trials ranging between children of 4.2 years and elderly subjects of 90 years.
Safety evaluations of Bifidobacterium lactis strains found them to be negative for mucin degradation and platelet aggregation test; the strains were susceptible to eight antibiotics; in accordance with the bacterial reversion mutation (Ames) assay, the tested strains had no genetic mutagenicity; and no dose-dependent mortality or toxicity was confirmed throughout multidose oral toxicity tests in rats.
In a phase I safety study conducted under FDA IND oversight, there was no difference in adverse events between the BB-12-supplemented and control groups, and there were no withdrawals from the study for adverse events related to product consumption.
The US FDA GRAS designation has been applied to certain probiotic organisms when added to food, although few systematic safety studies have been done, especially in vulnerable populations; a 2011 AHRQ report sponsored by the NIH and FDA, based on an exhaustive review of 622 studies of organisms from 6 genera including Bifidobacterium, addressed probiotic safety.
Immunocompromised individuals and critically ill patients may be at increased risk of invasive infection; clinical use in such populations should be under specialist guidance. Safety is considered excellent in healthy populations, but live probiotics should be avoided in severely immunocompromised patients or those with central venous catheters.
Because B. animalis subsp. lactis is a live microorganism, concurrent administration with antibiotics may reduce viable cell counts reaching the colon. Safety studies have confirmed susceptibility of tested B. lactis strains to multiple antibiotics. Spacing probiotic dosing from antibiotic dosing — and continuing probiotic administration after the antibiotic course ends — is a practical consideration reflected in clinical trial designs.
Efficacy and safety are strain-specific — data for one strain cannot be extrapolated to others. The NIH, including the National Center for Complementary and Integrative Health and Office of Dietary Supplements, recognizes that probiotics show promise for certain indications but emphasizes strain-specific evidence and calls for more rigorous clinical trials to substantiate many claims.
More studies are needed to elucidate the mechanistic pathways by which probiotics such as BB-12 can affect mucosal barrier functions and innate immunity.
Health conditions that Bifidobacterium lactis may help support.
Bifidobacterium lactis (animalis subsp. lactis) has demonstrated efficacy in reducing abdominal pain and IBS symptom severity in a large RCT. UABla-12 (1×10^10 CFU/day for 6 weeks) significantly improved IBS Symptom Severity Scale scores including abdominal pain subscores compared to placebo.
Clinical trials and narrative reviews support that Bifidobacterium lactis strains can reduce allergic rhinitis symptoms by modulating the Th1/Th2 immune balance and lowering serum IgE and IL-13. A randomized double-blind trial of B. lactis A6 in adults with perennial allergic rhinitis demonstrated significant symptom reduction. The gut-lung axis provides the mechanistic basis for systemic effects on airway allergy.
Preclinical studies show B. lactis strains reduce ovalbumin-induced allergic asthma markers in mice, including IgE, airway inflammation, and Th2 cytokines, partly through tryptophan metabolism. Human evidence is limited to indirect support from respiratory allergy trials; dedicated clinical asthma RCTs are lacking.
A crossover RCT of B. lactis TISTR 2591 in T2DM patients significantly attenuated fasting glucose elevation and improved HOMA-IR versus placebo. B. lactis HN019 in metabolic syndrome patients showed favorable trends in glucose metabolism. Evidence supports modest glycemic benefits as adjunctive therapy.
Bifidobacterium lactis NLS-SS was studied in a 2013 double-blind RCT in active celiac disease patients. A 2025 RCT in 85 CeD patients used B. lactis CCT 7858 with L. rhamnosus for 90 days, concluding probiotics are beneficial adjunct therapy for CeD symptom relief. A 2008 study demonstrated B. lactis inhibits the toxic effects of wheat gliadin in epithelial cell cultures.
Bifidobacterium lactis (also known as B. animalis subsp. lactis) has been studied in infants and children for allergy prevention and treatment. RCTs have found that supplementation with Lactobacillus rhamnosus HN001 and B. lactis HN019 perinatally reduced prevalence of early atopic dermatitis, with specific Toll-like receptor genetic variations associated with protection. It is also an ingredient in specialized infant formulas studied for atopic dermatitis reduction.
Bifidobacterium lactis (B. animalis subsp. lactis) is one of the most widely studied probiotic strains in pediatric medicine, evaluated in clinical trials for diarrhea, NEC, H. pylori eradication-associated diarrhea, and gut tolerance in infants. It is a common addition to infant formulas and pediatric probiotic supplements with substantial safety data.
Bifidobacterium lactis (animalis subsp. lactis) is among the most clinically validated probiotic strains for children's immune and respiratory health. A 2025 double-blind RCT in 120 children with recurrent RTIs found Bifidobacterium animalis subsp. lactis XLTG11 plus Lactiplantibacillus plantarum significantly reduced frequency and duration of respiratory infections, fever, cough, and pneumonia versus placebo. It strongly enhances secretory IgA levels.
B. lactis HN019 reduced total cholesterol and LDL-C in a randomized trial in metabolic syndrome patients. A meta-analysis of Bifidobacterium-containing probiotics in 24 RCTs found significant reductions in total cholesterol, LDL-C, and triglycerides. Results in normocholesterolemic individuals are less consistent.
A randomized trial of B. lactis HN019 in metabolic syndrome patients demonstrated significant reductions in TNF-α and IL-6 compared to baseline and control. A meta-analysis of Bifidobacterium-containing probiotic RCTs found significant reductions in hs-CRP, TNF-α, and IL-6. B. lactis strains also restored gut barrier integrity in preclinical models, reducing inflammatory signaling.
B. lactis BB-12 has been investigated in randomized trials for its effect on cold/flu incidence and severity in healthy adults; B. lactis Bl-04 significantly reduced the risk of upper respiratory illness in a large RCT. A pediatric RCT with a mixture including B. lactis HN019 shortened fever duration by approximately 2 days. Cochrane review evidence includes B. lactis strains for prevention of URTIs.
Bifidobacterium lactis BB-12 (Bifidobacterium animalis subsp. lactis) has been evaluated in dedicated double-blind RCTs for infantile colic with positive results. An 80-infant RCT found that B. lactis BB-12 at 10^9 CFU/day significantly reduced daily crying duration versus placebo starting from the second week. It is also incorporated in 2'-FL-supplemented formula studies for fussiness.
Bifidobacterium lactis (animalis subsp. lactis) has been specifically tested in a randomized, double-blind, placebo-controlled trial for collagenous colitis in combination with Lactobacillus acidophilus. It is among the most widely used Bifidobacteria strains in IBD probiotic research and multi-strain formulations for UC.
Bifidobacterium lactis (Bifidobacterium animalis subsp. lactis) is the single probiotic strain with the strongest individual evidence for improving stool frequency in chronic constipation. A 2022 systematic review of 30 RCTs identified B. lactis as the only individual strain achieving statistical significance for stool frequency improvement. Multiple dedicated RCTs with strains HN019 and UABla-12 confirm this finding.
Bifidobacterium lactis has clinical evidence for reducing acute infectious diarrhea duration in children. A Bayesian network meta-analysis of 84 RCTs (13,443 children) found it reduced diarrhea duration by approximately 0.98 days versus placebo (moderate GRADE certainty). It is also documented in Cochrane reviews of antibiotic-associated diarrhea prevention in children.
Bifidobacterium lactis (animalis subsp. lactis) has been studied in multiple RCTs for eczema prevention in high-risk infants and SCORAD reduction in children with atopic dermatitis. A 2019 RCT found a mixture of L. rhamnosus and B. animalis subsp. lactis reduced eczema incidence in infants over 6 months.
Bifidobacterium lactis is identified as a histamine-degrading probiotic strain relevant to histamine intolerance and food sensitivity management. It is among the probiotics that can degrade biogenic amines including histamine in the gut. Multiple reviews recognize its role in supporting gut microbiota diversity and reducing food-allergy-related atopic outcomes.
B. animalis subsp. lactis Bi-07 has been shown in two clinical trials and an EFSA review to support lactose digestion in individuals with lactose maldigestion, via β-galactosidase (lactase) activity. The strain was found to be superior to placebo and in one trial non-inferior to lactase supplementation for lactose digestion.
Bifidobacterium lactis is used in combination probiotic formulations shown in clinical trials to improve H. pylori eradication rates and reduce gastric mucosal inflammation. A prospective trial combining B. lactis with L. acidophilus, Lactiplantibacillus plantarum, and S. boulardii found improved H. pylori eradication and fewer adverse effects.
Bifidobacterium lactis is one of the most commercially studied probiotic species, with strong clinical evidence for modulating gut microbiota composition, improving stool consistency, enhancing intestinal barrier integrity, and reducing gut dysbiosis across multiple populations and conditions.
Bifidobacterium lactis is widely studied for gut health and has documented effects on the gut-brain axis through SCFA production, gut barrier enhancement, and immune modulation. Clinical fMRI evidence shows fermented milk products containing B. lactis strains reduce emotional brain activation. It is a common component of multi-strain psychobiotic formulations.
B. lactis HN019 significantly reduced BMI in a randomized trial in metabolic syndrome patients. Broader evidence from Bifidobacterium meta-analyses supports modest effects on adiposity in obese or metabolically compromised individuals, linked to shifts in gut microbiota composition and SCFA-mediated energy regulation.
Multiple RCTs have tested B. lactis strains in IBS patients. B. lactis BI040 in a 12-week RCT reduced pain frequency and intensity, while B. lactis UABla-12 improved abdominal pain severity. Meta-analyses of Bifidobacterium strains in IBS show limited but significant benefits over placebo, primarily for pain and global symptoms.
Bifidobacterium lactis is a well-studied probiotic strain with clinical evidence in UC, where it has been used in both standalone and combination probiotic formulations demonstrating improved clinical and endoscopic outcomes in IBD trials.
B. lactis TISTR 2591 improved HOMA-IR and enhanced β-cell function (HOMA-β) in a crossover RCT of T2DM patients. The proposed mechanism involves SCFA production, reduced gut permeability, and modulation of the inflammatory milieu that underlies insulin resistance.
Bifidobacterium lactis (Bi-07 strain) has the highest documented β-galactosidase activity among tested probiotic strains and was superior to placebo in two crossover RCTs for lactose intolerance. Multiple studies and a meta-analysis confirm its efficacy for reducing breath hydrogen and LI symptoms. It is one of the most-evidenced probiotic strains for this condition.
Bifidobacterium lactis (also designated B. animalis subsp. lactis) consistently appears in systematic reviews as one of the most effective probiotic strains for reducing intestinal permeability. It has been documented to restore intestinal barrier function in IBS, obese adults, and colon cancer patients in multiple high-quality clinical studies. A systematic review (ScienceDirect, 2023) identified Bifidobacterium, including B. lactis, as among the most common effective genera in positive clinical trials.
A randomized trial of B. lactis HN019 in 51 metabolic syndrome patients found significant reductions in BMI, total cholesterol, LDL, TNF-α, and IL-6 after 45 days. B. lactis strains thus address multiple components of MetS—dyslipidemia, inflammation, and central obesity—simultaneously.
Bifidobacterium lactis (including strains BB-12 and HN019) has been studied in multiple RCTs and in vitro for effects on the oral microbiome and periodontal health. BB-12 combined with L. rhamnosus GG altered oral microbiota in a 4-week RCT. B. lactis HN019 showed antimicrobial activity against P. gingivalis, P. intermedia, F. nucleatum, and A. actinomycetemcomitans in vitro and improved gingival inflammation in periodontitis patients.
Bifidobacterium lactis (B. animalis subsp. lactis, particularly strain BB-12) is one of the most widely used probiotic strains in pregnancy research. In a landmark Finnish RCT, formulations including B. lactis BB-12 significantly reduced GDM incidence (13% vs. 36%, p=0.003). It has also demonstrated improved neonatal gut colonization and reduced infantile atopic disease in multiple RCTs.
An exploratory RCT demonstrated that B. lactis NCC2818 mitigated immune parameters and allergic symptoms during seasonal grass-pollen exposure. The strain reduced markers of Th2 immune activation during the allergy season. Results are preliminary, warranting larger confirmatory trials.
A meta-analysis of Bifidobacterium-containing probiotic RCTs showed significant triglyceride reductions. B. lactis HN019 demonstrated favorable effects on blood lipids in metabolic syndrome patients. Effects appear more robust in individuals with pre-existing hypertriglyceridemia than in healthy normolipidemic individuals.
Multiple clinical trials, including a large RCT with B. lactis Bl-04 and combination trials with B. lactis BB-12 and HN019, demonstrate that B. lactis supplementation reduces the risk, duration, or severity of upper respiratory tract infections. Effects are linked to enhanced NK-cell function, secretory IgA, and mucosal immunity.
Bifidobacterium lactis was a component of the multi-strain probiotic in the 18-month double-blind RCT (181 children with febrile UTI) that achieved UTI-free survival in 96.7% vs. 83.3% placebo (p=0.02). It supports urinary flora through gut-urinary axis mechanisms — reducing the intestinal uropathogen reservoir and modulating immune responses relevant to urinary tract defense.
B. lactis strains enhance innate antiviral defenses by stimulating NK-cell activity and T-cell responses, and by elevating secretory IgA at mucosal surfaces. Clinical trial data show reduced viral URTI risk and improved immune cell function following B. lactis supplementation.
Body systems that Bifidobacterium lactis may help support.
Go back